Maximizing Utilization of Depression Screening in Lung Cancer Patients: A Randomized Trial
OBJECTIVES:
Primary
- Determine the impact of depression screening in patients with lung cancer when the
results of the screening are made available to the patient, the physician, both, or
neither on detection of depression, provision of depression treatment recommendations,
and the quality of the doctor-patient interaction from the patient's perspective.
Secondary
- Determine psychological and demographic subsets for the impact of depression screening
in these patients when the results of the screening are made available to the patient,
the physician, both, or neither on the detection of depression, provision of depression
treatment recommendations, and the quality of the doctor-patient interaction from the
patient's perspective.
OUTLINE: This is a multicenter, randomized, double-blind, single-blind, factorial study.
Patients are stratified according to participating center (Memorial Sloan-Kettering Cancer
Center vs University of Kentucky Markey Cancer Center). Patients are randomized to 1 of 4
screening arms.
- Arm I (control): Patients complete screening questionnaires about their mood and
experience with lung cancer once before and once after a visit with their physician.
Neither the patient nor physician receives the screening results before the visit.
- Arm II: Patients complete screening questionnaires as in arm I. Only the patient
receives the screening results before their visit with the physician; the physician
remains blinded to the results.
- Arm III: Patients complete screening questionnaires as in arm I. Only the physician
receives the screening results before their visit with the patient; the patient remains
blinded to the results.
- Arm IV: Patients complete screening questionnaires as in arm I. Both physician and
patient receive the screening results before the visit.
All patients and physicians are notified of the screening results before the patient leaves
the clinic. All patients are offered supportive counseling.
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Number of treatment recommendations for depression made as measured by checklist of recommendations for depression treatment
2 years
No
William Breitbart, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
Mskcc 06-038
NCT00404365
April 2006
April 2012
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Lucille P. Markey Cancer Center at University of Kentucky | Lexington, Kentucky 40536-0093 |